The multiple myeloma market is becoming increasingly crowded. In 2015, several new, high-priced therapies have been approved for in the treatment of multiple myeloma, making this lucrative market…
The 2014 multiple myeloma market garnered impressive sales despite its relatively low incidence compared with other oncology markets with similar revenues. Significant achievements in clinical…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (…
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…
What Attributes Will Distinguish Emerging Therapies in the Eyes of Hematological Oncologists and Payers? The introduction of the proteasome inhibitor bortezomib (Millennium/Takeda/Janssen’s…